Crowd Funding for Orphan Drugs: The Case of Baby Pia
- PMID: 34970148
- PMCID: PMC8712947
- DOI: 10.3389/fphar.2021.787342
Crowd Funding for Orphan Drugs: The Case of Baby Pia
Abstract
Medical crowdfunding is a relatively new strategy to obtain access to orphan drugs. The case of Baby Pia, a Belgian girl with SMA type 1 for whom in 2018 more than $ 2.1 million was raised to get her treated with Zolgensma®, illustrates well the potential power of medical crowdfunding. But apart from the success in raising money, the case is also of particular importance for the ethical issues it brings to the surface as related to justice, equity, power imbalances, responsibility, accountability, indebtedness and privacy.
Keywords: SMA; crowd funding; ethics; orphan drugs; rare diseases; zolgensma.
Copyright © 2021 Pinxten.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- Commission Regulation (EC) (2000). Commission Regulation (EC) No 847/2000 of 27 April 2000 Laying Down the Provisions for Implementation of the Criteria for Designation of a Medicinal Product as an Orphan Medicinal Product and Definitions of the Concepts ‘Similar Medicinal Product’ and ‘Clinical Superiority’ OJ L103, 5–8. (Accessed April 28, 2000).
LinkOut - more resources
Full Text Sources
